NIACINAMIDE 4% / TAZAROTENE 0.1%- niacinamide 4% / tazarotene 0.1% gel 
Sincerus Florida, LLC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

----------

NIACINAMIDE 4% / TAZAROTENE 0.1%

Directions for use

w

Sincerus Florida, LLC. Adverse reactions

ghv

Active, inactive

X

NDC 72934-1161-2 NIACINAMIDE USP 4% / TAZAROTENE 0.1%. Gel 30gm

f

NIACINAMIDE 4% / TAZAROTENE 0.1% 
niacinamide 4% / tazarotene 0.1% gel
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:72934-1161
Route of AdministrationTOPICAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
NIACINAMIDE (UNII: 25X51I8RD4) (NIACINAMIDE - UNII:25X51I8RD4) NIACINAMIDE4 g  in 100 g
TAZAROTENE (UNII: 81BDR9Y8PS) (TAZAROTENE - UNII:81BDR9Y8PS) TAZAROTENE0.1 g  in 100 g
Product Characteristics
Colorwhite (clear gel) Score    
ShapeSize
FlavorImprint Code
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:72934-1161-230 g in 1 BOTTLE, PUMP; Type 0: Not a Combination Product05/10/2019
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
unapproved drug other05/10/2019
Labeler - Sincerus Florida, LLC (080105003)
Establishment
NameAddressID/FEIBusiness Operations
Sincerus Florida, LLC080105003manufacture(72934-1161)

Revised: 5/2019
Document Id: 8878ee14-5817-5631-e053-2995a90ab73f
Set id: 8878ee14-5816-5631-e053-2995a90ab73f
Version: 1
Effective Time: 20190509
 
Sincerus Florida, LLC